Klaria Year-End Report Q4 2020

Summary of the year-end report

Initiated bioequivalence registration study with Sumatriptan Alginate Film

FOURTH QUARTER 2020 (OCTOBER–DECEMBER)

• Net sales amounted to 0.0 MSEK (0.1 MSEK)
• R&D costs for the period amounted to 17.6 MSEK (9.7 MSEK)
• Profit after tax amounted to -17.0 MSEK (-5.3 MSEK)
• Earnings per share for the quarter amounted to -0.34 SEK (-0.17 SEK)
• Cash flow from operating activities amounted to -10.1 MSEK (-5.7 MSEK)
• Cash and cash equivalents on the balance day amounted to 31.3 MSEK (2.9 MSEK)
• Shareholder’s equity per December 31, amounted to 109.6 MSEK (82.1 MSEK)∞ At an extraordinary general meeting on November 2, the board decided to issue 3,581,871 shares to an international consortium at a share price of 6.84 SEK, which provided the company with 29 MSEK in additional capital. After the decision ofthe share issue, the number of shares in the company amounts to 51,808,279 and the share capital amounts to 863,471.32 SEK.

THE PERIOD JANUARY–DECEMBER 2020

• Net sales amounted to 0.0 MSEK (4.2 MSEK)
• R&D costs for the period amounted to 48.4 MSEK (24.2 MSEK)
• Profit after tax amounted to -51.4 MSEK (-22.5 MSEK)
• Earnings per share for the quarter amounted to -1.19 SEK (-0.72 SEK)∞ Cash flow from operating activities amounted to -35.3 MSEK (-14.8 MSEK)∞ On February 24, 2020, the merger between Karessa Pharma Holding AB (publ) and Klaria Pharma Holding AB (publ), that received approval at extraordinary general meetings in the two companies, was completed. The merger was registered atBolagsverket as of March 6, 2020, and Karessa is thereby dissolved. The terms for the merger was that one share in Karessa was exchanged for 0.6032 new shares in Klaria. In connection with the merger, 6,635,200 new shares in Klaria were issuedto Karessa’s shareholders. After the merger has been completed, the number of shares in Klaria amounts to 38,728,448.
• In April, the company raised 17.1 MSEK through a directed issue of 5,697,960 shares at a price of 3 SEK per share.
• In July, the company raised 11.4 MSEK through a directed issue of 3,800,000 shares at a price of 3 SEK per share.
• At an extraordinary general meeting on November 2, the board decided to issue 3,581,871 shares to an internationalconsortium at a share price of 6.84 SEK, which provided the company with 29 MSEK in additional capital. After the decision of the share issue, the number of shares in the company amounts to 51,808,279 and the share capital amounts to 863,471.32 SEK.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.